|
Novogen
Marshall
Edwards
|
Novogen Limited and Marshall
Edwards, Inc. concluded a license agreement for MSHL
to develop and commercialize the two oncology compounds NV-196 and NV-143,
for for pancreatic and bile duct cancer and
melanoma, respectively. (May 15)
|
|
|
Read
more...
|
|
|
|
|
AlphaRx
PharmaSeed
|
AlphaRx Inc. announced a collaboration with PharmaSeed
Ltd. for the development of new drugs for the potential treatment of CNS
disorders such as stroke and multiple sclerosis. (May 11)
|
|
|
Read
more...
|
|
|
|
|
Kissei
Daiichi
|
Kissei Pharmaceutical and Daiichi
Pharmaceutical announced that they will jointly launch URIEF
Cap. 2mg/ 4mg (silodosin), an agent for treating
urination disorder associated with benign prostatic
hypertrophy (BPH). (May 10)
|
|
|
Read
more...
|
|
|
|
|
Kaken
Dow
|
Kaken Pharmaceutical announced a
licensing agreement with Dow Pharmaceutical Sciences for KP-103, Kaken's
proprietary antifungal compound. (May 11)
|
|
|
Read more...
|
|
|
|
|
Eisai
Nitto
Denko
|
Eisai announced a joint research
agreement with Nitto Denko under which the two companies will collaborate
in developing a transdermal formulation (adhesive tape) of ARICEPT, an agent for treating Alzheimer's disease.
(May 11)
|
|
|
Read more...
|
|
|
|
|
UCB
Immunomedics
|
UCB Group and
Immunomedics, Inc. announced a collaboration and license agreement for
Immunomedics' lead product, epratuzumab, granting
UCB the exclusive worldwide rights to develop, market and sell epratuzumab
for all autoimmune disease indications. (May 10)
|
|
|
Read
more...
|
|
|
|
|
Unigene
Tzamal
|
Unigene Laboratories, Inc.
entered into an exclusive distribution agreement with Tzamal
Bio Pharma Ltd. to distribute its Fortical® nasal
spray in Israel for the treatment of
osteoporosis. (May 10)
|
|
|
Read
more...
|
|
|
|
|
Oxford
Medarex
|
Oxford Genome Sciences (UK) Ltd.
and Medarex, Inc. announced a strategic
collaboration to discover and develop new human antibody therapeutics for
the treatment of cancers, including colorectal cancer. (May 10)
|
|
|
Read
more...
|
|
|
|
|
NephroGenex
BioStratum
|
NephroGenex, Inc. announced a
licensing agreement with BioStratum Incorporated
that acquires commercial rights to Pyridorin™ (pyridoxamine dihydrochloride)
for diabetic nephropathy.(May 10)
|
|
|
Read more...
|
|
|
|
|
Labopharm
Grunenthal
|
Labopharm Inc. announced a
licensing and distribution agreement with Grunenthal
GmbH for its once-daily tramadol product for Belgium. (May 9)
|
|
|
Read more...
|
|
|
|
|
Angiotech
Genzyme
|
Angiotech Pharmaceuticals, Inc.
and Genzyme Corporation announced a strategic
collaboration agreement designed to identify, develop and commercialize
innovative therapies for cancer patients undergoing surgical removal of tumors. (May 9)
|
|
|
Read
more...
|
|
|
|
|
Kos
SkyePharma
|
Kos Pharmaceuticals, Inc.
and SkyePharma Inc. signed an exclusive license
agreement for the marketing and distribution of Flutiform™
in the United States. (May 8)
|
|
|
Read more...
|
|
|
|
|
Inex
Hana
|
Inex Pharmaceuticals
Corporation announced the closing of a transaction to license three
products from its targeted chemotherapy pipeline to Hana Biosciences, Inc.,
under which Inex grants Hana a worldwide license
to develop and commercialize Marqibo™ (sphingosomal vincristine),
INX-0125 (sphingosomal vinorelbine)
and INX-0076 (sphingosomal topotecan).
(May 8)
|
|
|
Read
more...
|
|
|
|
|
ULURU
BioProgress
|
ULURU Inc. announced a
joint strategic development agreement with BioProgress
plc under which the companies will initially work together to develop an
anti-emetic product for the relief of nausea, using a combination of BioProgress' film technology and ULURU's
Oradisc™ drug delivery technology. (May 4)
|
|
|
Read more...
|
|
|
|
|
RHEI
Flamel
|
RHEI Pharmaceuticals, Inc.
and Flamel Technologies, S.A. announced that RHEI has licensed from Flamel
the exclusive right to market Asacard®, a
controlled release formulation of aspirin, in the Greater China region
(including China, Taiwan, Hong Kong and Macau). (May 4)
|
|
|
Read
more...
|
|
|
|
|
Abeille
|
Abeille Pharmaceuticals, Inc.
announced an agreement granting Abeille
worldwide, exclusive rights to a technology platform for transdermal patch
applications. (May 3)
|
|
|
Read more...
|
|
|
|
|
Genzyme
Brookwood
|
Genzyme Pharmaceuticals and Brookwood Pharmaceuticals, Inc. announced a broad
collaboration to develop novel drug delivery solutions, with an initial
focus on peptide delivery. (May 2)
|
|
|
Read more...
|
|
|
|
|
Akorn
Fidia
|
Akorn, Inc. announced a
definitive agreement with Fidia Farmaceutici
S.p.A. to develop four ANDA drug products.(May 2)
|
|
|
Read more...
|
|
|
|
|
IntelliPharmaCeutics
Larasan
|
IntelliPharmaCeutics Corp. announced a new
agreement with Larasan Pharmaceutical Corporation
for the development of a controlled release analgesic product for the United States and worldwide
markets. (May 2)
|
|
|
Read more...
|
|
|
|
|
PainCeptor
Argenta
|
PainCeptor Pharma Corp.
announced a development collaboration with Argenta Discovery Ltd. for pain therapeutics, targeting
sensory mechanisms which are associated with a variety of pain-related
conditions, including cancer and arthritis. (May 2)
|
|
|
Read
more...
|
|
|
|
|
AlphaRx
|
AlphaRx Inc. announced an
agreement with a leading Chinese marketing company to establish a Joint
Venture Company in China for the purpose of
manufacturing, marketing and distributing pharmaceutical and consumer
health products in Asia. (May 1)
|
|
|
Read more...
|
|
|
|
|
FibroGen
Astellas
|
FibroGen, Inc. announced an
exclusive licensing agreement with Astellas
Pharma Inc. that provides Astellas rights to
certain FibroGen hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors for development and
marketing for the treatment of anemia in Europe, Commonwealth of Independent
States (CIS), Middle East, and South Africa. (Apr 28)
|
|
|
Read more...
|
|
|
|
|
Acuity
ZaBeCor
|
Acuity Pharmaceuticals announced
a license option agreement with ZaBeCor
Pharmaceutical Co. for exclusive development and commercialization rights
to ophthalmic applications of a novel agent with the potential to treat a
variety of inflammatory disorders. (Apr 28)
|
|
|
Read more...
|
|
|
|
|
Abraxis
AstraZeneca
|
Abraxis BioScience, Inc. announced an agreement with AstraZeneca for the co-promotion of Abraxis'
proprietary drug ABRAXANE® in the United
States, as well as an agreement
to acquire AstraZeneca's U.S. branded
anesthetic and analgesic injectable portfolios. (Apr 26)
|
|
|
Read more...
|
|
|
|
|
Ilypsa
Astellas
|
Ilypsa, Inc.
and Astellas Pharma Inc. announced a license
agreement that gives Astellas exclusive rights to
develop and market ILY101 in Japan, a drug
to treat hyperphosphatemia which was discovered
by and is under development by Ilypsa. (Apr 27)
|
|
|
Read more...
|
|
|
|
|
Advitech
Enbio-Life
|
Advitech Inc.
announced an agreement in principle for the marketing and distribution of Dermylex™ by Enbio-Life
Biotechnology & Medical Company Ltd. in the Taiwanese market and with
an option for the market in China as well.
(Apr 26)
|
|
|
Read more...
|
|
|
|
|
ImQuest
Samjin
|
ImQuest
Pharmaceuticals, Inc. announced an exclusive worldwide license for the
development and commercialization of anti-cancer agents discovered and
patented by Samjin Pharmaceutical Co. Ltd. (Apr
26)
|
|
|
Read more...
|
|
|
|
|
Argos
Beckman Coulter
|
Argos Therapeutics, Inc.
announced an agreement with Beckman Coulter granting Argos exclusive
therapeutic use rights for the soluble protein, CD83, including use as a therapy
for autoimmune disorders and transplant rejection. (Apr 26)
|
|
|
Read
more...
|
|
|
|
|
Lexicon
Cetek
|
Lexicon Genetics Incorporated
and Cetek Corporation announced an agreement
under which Cetek will provide Lexicon with a
library derived from natural products for use by Lexicon in drug discovery.
(Apr 26)
|
|
|
Read
more...
|
|
|
|
|
Five Prime
Boehringer
|
Five Prime Therapeutics, Inc.
announced a collaborative research and license agreement with Boehringer
Ingelheim to discover novel therapeutic products to treat rheumatoid
arthritis and other diseases. (Apr 25)
|
|
|
Read
more...
|
|
|
|
|
BioProgress
Cristers
|
BioProgress plc signed a
strategic partnership agreement with Cristers for
the promotion and distribution of its over-the-counter Soluleaves™
products in France. (Apr 25)
|
|
|
Read
more...
|
|
|
|
|
Isotechnica
Cellgate
|
Isotechnika Inc. announced an
option agreement with Cellgate Inc. allowing Isotechnika the option to obtain an exclusive license
to develop and commercialize conjugates consisting of Cellgate's
patented transporter technology for the topical
delivery of ISA247 in patients suffering from mild to moderate psoriasis.
(Apr 25)
|
|
|
Read
more...
|
|
|
|
|
Alcon
Amgen
|
Alcon, Inc. and Amgen
announced a broad, multi-target collaboration to jointly research, develop,
and commercialize therapeutics for the treatment of eye diseases. (Apr
24)
|
|
|
Read
more...
|
|
|
|
|
Cytogen
Savient
|
Cytogen
Corporation and Savient Pharmaceuticals announced
a distribution agreement granting Cytogen
exclusive marketing rights for SOLTAMOX™ (tamoxifen citrate) in the United
States. (Apr 24)
|
|
|
Read
more...
|
|
|
|
|
AlphaRx
New Super
|
AlphaRx Inc.
announced a term sheet agreement with New Super Limited for the purpose of
funding AlphaRx's ongoing business developments
and commercialization of its licensed products in its pharmaceutical and
consumer health product line in Asia. (Apr
24)
|
|
|
Read more...
|
|
|
|
|
Akorn
Natco
|
Akorn, Inc.
announced an API supply and margin sharing agreement with Natco Pharma Limited to commercialize two ANDA injectable drug products. (Apr 21)
|
|
|
Read more...
|
|
|
|
|
Japan Tobacco
GSK
|
Japan Tobacco signed a licensing
agreement with GlaxoSmithKline for a candidate compound developed by JT.
(Apr 20)
|
|
|
Read more...
|
|
|
|
|
MedImmune
Elusys
|
MedImmune, Inc.
announced an exclusive licensing and collaboration agreement with Elusys Therapeutics, Inc. for select infectious disease
targets. (Apr 20)
|
|
|
Read
more...
|
|
|
|
|
Acuity
Pathogenics
|
Acuity Pharmaceuticals, Inc.
announced that it has in-licensed from Pathogenics,
Inc. the exclusive worldwide development and commercialization rights to N-chlorotaurine (NCT), a novel,
clinical stage, small molecule agent for the treatment of ophthalmic
infections and other conditions. (Apr 20)
|
|
|
Read more...
|
|
|
|
|
Isis
ImQuest
|
Isis Pharmaceuticals, Inc. and ImQuest Pharmaceuticals Inc. announced that Isis has
granted an exclusive worldwide license to ImQuest
for the development and commercialization of ISIS 5320, an inhibitor of
HIV. (Apr 18)
|
|
|
Read
more...
|
|
|
|
|
Dainippon Sumitomo
Eisai
|
Dainippon Sumitomo Pharma Co.,
Ltd. and Eisai Co., Ltd. announced a licensing agreement regarding Gasmotin (mosapride citrate),
a gastroprokinetic agent, for countries including
ASEAN members such as Indonesia, Thailand and the Philippines. (Apr
17)
|
|
|
Read
more...
|
